Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



Education Initiative in Women's Health

  • Endometrial Cancer — Second-Line Treatment of a Patient With Advanced Endometrial Cancer With Mismatch Repair Deficiency – @Point of Care Chapter
  • A proportion of patients with endometrial cancer have tumors with deficient mismatch repair. For these patients, the high tumor mutational burden results in high levels of neoantigens that may make them susceptible to immunotherapy. In this case study, please join Ramez Eskander, MD, in following a 54-year- ... more >>
  • Endometrial Cancer — Management of a Patient With Advanced MSS/MMRp Endometrial Cancer Experiencing a Relapse – @Point of Care Chapter
  • Use of immunotherapy has revolutionized treatment strategies for many cancers, including endometrial cancer. Recently, combination therapy with the immune checkpoint inhibitor pembrolizumab and the anti-angiogenic agent lenvatinib was approved for the treatment of mismatch repair proficient (MMRp) endometrial ... more >>
    S. Westin, MD, MPH
  • Endometrial Cancer — Treatment Strategies for Managing Advanced Endometrial Cancer – @Point of Care Chapter
  • Endometrial cancer is the most common malignancy of the female genital tract, leads the distinguished set of five tumor types that has been increasing in mortality rate, and, like many other tumors, has significant health disparities. However, the past few years have seen the development and approval of ... more >>
    R. Coleman, MD
  • Breast Cancer — Immune Checkpoint Inhibition for TNBC – @Point of Care Chapter
  • The past several years have seen the approval of treatments for subsets of patients with advanced triple-negative breast cancer (TNBC), including the immune checkpoint inhibitors atezolizumab and pembrolizumab. In this activity, Dr. Hope Rugo reviews the approved uses of immune checkpoint inhibitors in TNBC, ... more >>
    H. Rugo, MD
  • Breast Cancer — Case Study: Management of Metastatic Triple-Negative Breast Cancer Associated With Germline BRCA1 Mutation – @Point of Care Chapter
  • Around 10% to 15% of breast cancers are triple-negative breast cancer (TNBC): negative for estrogen and progesterone hormone receptors and human epidermal growth factor receptor 2 (HER2). Approximately 10% to 20% of patients with TNBC have an inherited (germline) mutation in the BReast CAncer gene (BRCA) 1 or ... more >>
  • Breast Cancer — Management of a Patient With HR-Positive, HER2-Negative Metastatic Breast Cancer With Disease Progression After Endocrine Therapy – @Point of Care Chapter
  • The approval of cyclin dependent kinase 4/6 (CDK4/6) inhibitors in multiple clinical settings has changed the treatment paradigm for women with hormone receptor-positive advanced or metastatic breast cancer, for whom the prognosis has historically been poor. Join Dr. Adam Brufsky as he presents a case study ... more >>
    A. Brufsky, MD, PhD
  • Breast Cancer — New Considerations in TNBC – @Point of Care Chapter
  • Compared with other forms of breast cancer, triple negative breast cancer (TNBC) is more aggressive, and has had fewer treatment options. However, the past several years have seen the development and approval of new targeted treatment for subsets of patients with advanced TNBC, and other agents and ... more >>
  • Breast Cancer — Case Study: Optimizing the Management of HR-positive, HER2-negative Early Breast Cancer – @Point of Care Chapter
  • More than 70% of human breast cancers are hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative. Patients with localized, early-stage HR-positive/HER2-negative breast cancer can have high risk of disease recurrence after successful initial therapy. Join Laura M. Spring, MD, ... more >>
    L. Spring, MD
  • Breast Cancer — HR-Positive Advanced or Metastatic Breast Cancer: Use and Sequencing of Kinase Inhibitors – @Point of Care Chapter
  • Approved cyclin dependent kinase 4/6 (CDK4/6) inhibitors—including abemaciclib, palbociclib, and ribociclib—in combination with endocrine therapy are now considered standard of care for first-line treatment of patients with hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)- ... more >>
    H. Burstein, MD, PhD
  • Breast Cancer — Case Study: Management of a Patient With Previously Untreated Metastatic PD-L1 Positive TNBC – @Point of Care Chapter
  • Triple negative breast cancer (TNBC) is more aggressive, associated with poorer prognosis, and has fewer treatment options than other subtypes of breast cancer. In recent years, two immunotherapies have been approved in combination with chemotherapy for the first-line treatment of advanced or metastatic TNBC ... more >>
    E. Hamilton, MD
  • Ovarian Cancer @Point of Care
  • Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly.
    B. Monk, MD, FACS, FACOG
  • Breast Cancer @Point of Care
  • A vast body of knowledge has accumulated over the decades of research that have been conducted on the etiology and pathogenesis of breast cancer. In spite of this, the etiology and underlying causes of breast cancer are not well-understood. This chapter will examine risk factors for breast cancer as well as ... more >>
    F. Esteva, MD, PhD
  • Breast Cancer — Targeting HER3 in Breast Cancer – Webcast
  • The human epidermal growth factor receptor (HER) family of tyrosine kinases plays an essential role in regulation of cell growth and survival, and dysregulation can lead to tumorigenesis and metastasis. HER3 is overexpressed in the majority of breast cancers, and a correlation has been shown between elevation ... more >>
    J. O'Shaughnessy, MD
  • Breast Cancer — Considerations for CDK4/6 Inhibitors in the Neoadjuvant and Adjuvant Settings of Hormone Receptor-Positive Breast Cancer – Webcast
  • This activity involves a discussion about the ongoing adjuvant clinical trials of cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor-positive advanced or metastatic breast cancer, including the recent data from important subgroup analyses included in clinical trials. Key differences ... more >>
    I. Mayer, MD, MSCI
    H. Rugo, MD
  • Breast Cancer — Approved CDK4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Breast Cancer – Webcast
  • This activity involves a discussion about the evidence base for the use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6) in patients with hormone receptor-positive advanced or metastatic breast cancer, including the recent data from important subgroup analyses included in clinical trials. In addition, ... more >>
    I. Mayer, MD, MSCI
  • Breast Cancer — Blocking CDK4/6 and PI3K in Hormone Receptor-Positive Breast Cancer to Improve Outcomes – Webcast
  • This activity involves a discussion about the evidence base for the use of phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)-targeted therapies in patients with hormone receptor-positive breast cancer, including the importance of genetic testing to identify important genetic ... more >>
    I. Mayer, MD, MSCI
  • Ovarian Cancer — Special Considerations in Covid-19: Oncology – Webcast
  • On December 31, 2019 the Wuhand Municipal Health Commission, China, reported a cluster of cases of a novel coronavirus in Wuhan and on March 11, 2020 the World Health Organization declared Covid-19 a pandemic. Since that time US clinicians have faced unique challenges in daily practice. In this exclusive ... more >>
    R. Coleman, MD
  • Endometrial Cancer — Classification of Endometrial Cancers: Biomarkers and Tests – Webcast
  • Immune checkpoint inhibitor therapies are an exciting newer treatment modality for patients with endometrial cancer. In this video presentation, Drs. Douglas Levine and Dmitriy Zamarin will discuss use of biomarkers to help classify patients with endometrial cancer and select appropriate, personalized ... more >>
    D. Levine, MD
  • Endometrial Cancer — Management of Endometrial Cancer Using Immunotherapies – Webcast
  • Immune checkpoint inhibitor therapies are an exciting newer treatment modality for patients with endometrial cancer. In this video presentation, Drs. Douglas Levine and Dmitriy Zamarin will discuss the science behind immune checkpoint inhibition, as well as clinical data on approved and emerging immune ... more >>
    D. Levine, MD
  • Endometrial Cancer — Management of Immune-Related Adverse Effects in Endometrial Cancer – Webcast
  • Immune checkpoint inhibitor therapies are an exciting newer treatment modality for patients with endometrial cancer. In this video presentation, Drs. Douglas Levine and Dmitriy Zamarin will discuss the unique adverse effects that can arise with use of immune checkpoint inhibitors, and recommended management ... more >>
    D. Levine, MD
  • Ovarian Cancer — Charting a Course for BRCA and Beyond in Front-line Maintenance Therapy for Ovarian Cancer – Webcast
  • This activity involves a discussion about the evidence base for the use of bevacizumab or poly (ADP-ribose) polymerase (PARP) inhibitors as frontline maintenance therapy for ovarian cancer. Recent FDA approvals for PARP inhibitors alone and in combination with bevacizumab and the data supporting these ... more >>
    B. Monk, MD, FACS, FACOG
    K. Moore, MD
  • Ovarian Cancer — Innovations in Ovarian Cancer Care: Integrating New Therapies Into Real-World Care – Webcast
  • This activity is a discussion about advances in our understanding of the molecular landscape of ovarian cancer and how poly (ADP-ribose) polymerase inhibitors are designed to target the genomic instability within tumors, resulting in synthetic lethality. The importance of germline and somatic testing of women ... more >>
    B. Monk, MD, FACS, FACOG
    K. Moore, MD
  • Ovarian Cancer — Combination First-Line Maintenance Therapy in Ovarian Cancer – Case Study
  • The landscape of first-line maintenance therapy for advanced ovarian cancer has rapidly evolved. Whereas options were previously limited to olaparib for patients with BRCA mutations and bevacizumab for those without, two new poly (ADP-ribose) polymerase (PARP) inhibitor-based regimens have been approved as ... more >>
    L. Randall, MD, MAS
  • Uterine Fibroids — Strategies for Relief: New Approaches to Uterine Fibroids Clinical Highlights from Live Meeting – October 2017
  • Significant progress has recently been made in the management of uterine fibroids, including the development of minimally invasive procedures, fertility-sparing techniques, and pharmacologic options that hold substantial promise to improve morbidity, symptom severity, and quality of life for women with ... more >>
    A. Al-Hendy, MD, PhD
    W. Catherino, MD, PhD
  • Gynecologic Cancers — Treatment of Recurrent Stage IIIB Cervical Adenoma – Case Study
  • This case illustrates the real-life scenario of a woman with cervical adenocarcinoma that recurs outside of the initial treatment field following initially successful definitive chemoradiation treatment. Treatment with systemic chemotherapy is warranted in such circumstances, but various options and ... more >>
    R. Coleman, MD
  • Gynecologic Cancers — Treatment of a Patient with Platinum-Resistant Recurrent Ovarian Cancer – Case Study
  • Although progress has been made in the treatment of ovarian cancer, the majority of patients still experience disease recurrence. More and more frequently, these patients receive multiple lines of treatment. This case illustrates the real-life scenario of a woman who experiences multiple recurrences of her ... more >>
    R. Coleman, MD
  • Gynecologic Cancers — Treatment of Recurrent Cervical Squamous Cell Carcinoma – Case Study
  • Women with recurrent cervical cancer have limited treatment options. Most women with recurrent disease have undergone prior chemoradiation, which can lead to platinum resistance. This case illustrates the real-life scenario of a woman who experiences a recurrence of her cervical squamous cell carcinoma after ... more >>
    B. Monk, MD, FACS, FACOG
  • Gynecologic Cancers — Treatment of Platinum-Resistant Recurrent Ovarian Epithelial Cancer – Case Study
  • Women with recurrent ovarian cancer have limited treatment options and a poor prognosis. This case illustrates the real-life scenario of a woman who experiences platinum-resistant recurrent ovarian cancer and addresses the treatment options, including the use of the targeted antiangiogenic agent bevacizumab, ... more >>
    B. Monk, MD, FACS, FACOG

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information